Atea Pharmaceuticals Inc (AVIR)
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on oral antiviral medicines for serious viral infections. The company’s lead program is a combination regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is being evaluated in a Phase 3 clinical trial for hepatitis C virus (HCV). Atea is also developing AT-587, a candidate in Phase 1 testing for chronic hepatitis E virus (HEV) infection. Beyond its pipeline, the company maintains a proprietary platform of nucleosides and nucleotides used in virology, medicinal chemistry, and antiviral drug development. Atea also has a license agreement with MSD International GmbH covering the development, manufacturing, and commercialization of ruzasvir. Incorporated in 2012, Atea Pharmaceuticals is headquartered in Boston, Massachusetts, and its common stock trades on NASDAQ under the ticker AVIR.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AVIR
|
$4.98
|
4.1% Upside
|
Fair
|
$8.67
|
81.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-2.3x
|
1.6x
|
—
|
382.1 M
|
126.8 M
|
0.2%
|
75.0%
|
2.6
|
—
|
87.2%
|
